Categories
Nevin Manimala Statistics

Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD)

Cell Immunol. 2021 Mar 23;364:104345. doi: 10.1016/j.cellimm.2021.104345. Online ahead of print.

ABSTRACT

Previously, we generated IL233, a hybrid cytokine composed of interleukin (IL)-2 and IL-33, with better therapeutic potential than either cytokine in multiple inflammatory diseases, in part through promoting T-regulatory cells (Tregs). Here we test the potential of IL233 pretreatment in a murine model of excessive Th1 activation, the parent-into-F1 model of acute GVHD (aGVHD). Five days of IL233 pretreatment of the recipients blocked or delayed the aGVHD-linked loss of B cells as seen in either the peripheral blood (day-11) or lymph nodes (day-14). IL233 pretreatment also prevented the expansion of donor CD8 T-cells in blood and LN at day-14 and significantly reduced day-14 serum IFNγ and TNFα compared to saline treated GVHD mice although, the level of Tregs did not statistically differ between saline and IL233-treated mice. Overall, the current study provides support for the use of IL233 as a therapeutic option in excessive Th1/CD8-driven conditions.

PMID:33831754 | DOI:10.1016/j.cellimm.2021.104345

By Nevin Manimala

Portfolio Website for Nevin Manimala